Elyxyb Now Available for Acute Migraine Treatment
Elyxyb is a ready-to-use oral solution formulation of celecoxib.
Diagnosis & Disease Information
Various Strategies Used by US Adults to Manage Chronic Pain
54.7 percent used only nonopioid pain management strategies and 4.4 percent used opioids only
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Vitamin D Supplementation Could Reduce Migraine Headache Attacks
Vitamin D supplementation had no obvious effect on attack duration or headache severity
Significant Pain Relief Observed With Intranasal Zavegepant in Migraine Trial
Zavegepant is an investigational calcitonin gene-related peptide (CGRP) receptor antagonist.
MPR Weekly Dose Podcast Episode 99
This week on the pod, there’s positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.
Erenumab vs Topiramate in Patients With Migraine: Head-to-Head Study Results
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Qulipta Approved for Preventive Treatment of Episodic Migraine
Results from ADVANCE showed statistically significantly greater decreases in mean monthly migraine days with atogepant compared with placebo.
Trudhesa Nasal Spray Now Available for Acute Treatment of Migraine
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.
Migraine Management: How to Treat Patients With Vascular Disease
The use of triptans is contraindicated in patients with migraine and a history of ischemic stroke or coronary artery disease, although there’s no substantial evidence that they directly increase the risk for vascular events.
